| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $7,781,340 | 2 | 17 |
Sells | $10,109,670 | 10 | 83 |
| WALTERS GROUP | 10 percent owner | 1 | $7.75M | 0 | $0 | $7.75M |
| Myers Scott Dunseth | director | 1 | $29,373 | 0 | $0 | $29,373 |
| Bruns Ingmar | Chief Medical Officer | 0 | $0 | 2 | $7,998 | $-7,998 |
| EASTLAND JULIA MARIE | CEO & President | 0 | $0 | 2 | $21,239 | $-21,239 |
| Vultaggio Vincent | PAO and PFO | 0 | $0 | 5 | $105,432 | $-105,432 |
| Matrix Capital Management Company, LP | 10 percent owner | 0 | $0 | 1 | $9.97M | $-9.97M |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Over the last 12 months, insiders at Zentalis Pharmaceuticals, Inc. have bought $7.78M and sold $10.11M worth of Zentalis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Zentalis Pharmaceuticals, Inc. have bought $29.15M and sold $14.18M worth of stock each year.
Highest buying activity among insiders over the last 12 months: WALTERS GROUP (10 percent owner) — $7.75M. Myers Scott Dunseth (director) — $29,373.
The last purchase of 6,459,973 shares for transaction amount of $7.75M was made by WALTERS GROUP (10 percent owner) on 2025‑12‑31.
| 2026-02-10 | Sale | Vultaggio Vincent | PAO and PFO | 6,894 0.0096% | $2.42 | $16,699 | +0.25% | |
| 2026-02-09 | Sale | Vultaggio Vincent | PAO and PFO | 3,379 0.0047% | $2.39 | $8,086 | +0.76% | |
| 2026-02-09 | Sale | EASTLAND JULIA MARIE | CEO & President | 889 0.0012% | $2.39 | $2,127 | +0.76% | |
| 2026-02-09 | Sale | Bruns Ingmar | Chief Medical Officer | 335 0.0005% | $2.39 | $802 | +0.76% | |
| 2026-02-06 | Sale | Vultaggio Vincent | PAO and PFO | 29,951 0.0421% | $2.43 | $72,772 | +6.89% | |
| 2026-02-06 | Sale | EASTLAND JULIA MARIE | CEO & President | 7,866 0.0111% | $2.43 | $19,112 | +6.89% | |
| 2026-02-06 | Sale | Bruns Ingmar | Chief Medical Officer | 2,962 0.0042% | $2.43 | $7,197 | +6.89% | |
| 2026-02-03 | Sale | Vultaggio Vincent | PAO and PFO | 556 0.0007% | $2.52 | $1,398 | -3.95% | |
| 2026-02-02 | Sale | Vultaggio Vincent | PAO and PFO | 2,540 0.0036% | $2.55 | $6,477 | -5.26% | |
| 2025-12-31 | WALTERS GROUP | 10 percent owner | 6.46M 8.0671% | $1.20 | $7.75M | +84.41% | ||
| 2025-12-15 | Sale | Matrix Capital Management Company, LP | 10 percent owner | 7.5M 9.8968% | $1.33 | $9.97M | +72.86% | |
| 2025-04-30 | Myers Scott Dunseth | director | 21,000 0.0288% | $1.40 | $29,373 | +2.82% | ||
| 2025-02-06 | Bruns Ingmar | Chief Medical Officer | 20,000 0.0299% | $2.28 | $45,656 | -31.94% | ||
| 2025-02-03 | Sale | Paul Andrea | Chief Legal Officer | 13,230 0.0183% | $1.71 | $22,643 | -12.50% | |
| 2025-02-03 | Sale | Lackner Mark | Chief Scientific Officer | 14,368 0.0198% | $1.71 | $24,591 | -12.50% | |
| 2025-02-03 | Sale | Vultaggio Vincent | PAO and Interim PFO | 2,615 0.0036% | $1.71 | $4,476 | -12.50% | |
| 2025-01-31 | Skvarka Jan | director | 60,000 0.0874% | $1.72 | $103,446 | -15.80% | ||
| 2025-01-31 | Walker Luke Nathaniel | director | 14,200 0.0211% | $1.76 | $24,966 | -15.80% | ||
| 2025-01-31 | EASTLAND JULIA MARIE | CEO & President | 28,500 0.0417% | $1.73 | $49,345 | -15.80% | ||
| 2025-01-02 | Sale | Lackner Mark | Chief Scientific Officer | 4,411 0.0065% | $3.12 | $13,762 | -51.00% |
| WALTERS GROUP | 10 percent owner | 13509973 18.6987% | $31.01M | 1 | 0 | |
| Matrix Capital Management Company, LP | 10 percent owner | 6459973 8.941% | $14.83M | 1 | 1 | <0.0001% |
| Myers Scott Dunseth | director | 281192 0.3892% | $645,335.64 | 1 | 0 | |
| Vultaggio Vincent | PAO and PFO | 146506 0.2028% | $336,231.27 | 0 | 7 | |
| EASTLAND JULIA MARIE | CEO & President | 79133 0.1095% | $181,610.24 | 1 | 2 | <0.0001% |
| Bruns Ingmar | Chief Medical Officer | 33332 0.0461% | $76,496.94 | 1 | 2 | <0.0001% |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 3943284 5.4578% | $9.05M | 1 | 1 | +70.78% |
| SUN ANTHONY Y | President & CEO | 1175589 1.6271% | $2.7M | 1 | 30 | +70.78% |
| Paul Andrea | Chief Legal Officer | 1070784 1.482% | $2.46M | 0 | 2 | |
| Bunker Kevin D. | Chief Scientific Officer | 859089 1.189% | $1.97M | 1 | 41 | +70.78% |
| Gallagher Cam | President, Interim CFO | 633680 0.8771% | $1.45M | 0 | 46 | |
| Lackner Mark | Chief Scientific Officer | 512856 0.7098% | $1.18M | 0 | 3 | |
| Epperly Melissa B, | Chief Financial Officer | 451449 0.6248% | $1.04M | 3 | 18 | +21.94% |
| HAUSMAN DIANA | Chief Medical Officer | 373876 0.5175% | $858,045.42 | 0 | 1 | |
| Blackwell Kimberly | Chief Executive Officer | 254800 0.3527% | $584,766.00 | 1 | 4 | +9.75% |
| Skvarka Jan | director | 149551 0.207% | $343,219.55 | 1 | 1 | <0.0001% |
| Johnson David Michael | director | 144389 0.1998% | $331,372.76 | 2 | 3 | +42.68% |
| Brownstein Carrie | Chief Medical Officer | 105685 0.1463% | $242,547.08 | 0 | 1 | |
| Walker Luke Nathaniel | director | 86681 0.12% | $198,932.90 | 1 | 0 | <0.0001% |
| Pinto Alexis | Chief Legal Officer | 22240 0.0308% | $51,040.80 | 0 | 2 | |
| Voliotis Dimitris | SVP, Clinical Development | 15978 0.0221% | $36,669.51 | 0 | 4 |
$48,218,096 | 42 | 0.89% | $140.31M | |
$16,259,194 | 41 | 120.51% | $177.64M | |
$109,415,500 | 33 | 18.13% | $152.66M | |
$47,292,212 | 27 | -28.21% | $158.53M | |
$167,701,902 | 27 | -3.07% | $178.25M | |
$295,092,700 | 21 | -0.27% | $154.63M | |
$38,821,584 | 20 | -2.17% | $141.07M | |
$111,692,551 | 18 | 13.51% | $147.94M | |
$448,999,793 | 15 | -19.99% | $177.57M | |
Zentalis Pharmaceuticals, Inc. (ZNTL) | $135,812,721 | 14 | 17.52% | $165.82M |
$13,259,565 | 14 | -30.38% | $178.12M | |
$15,799,576 | 12 | -39.52% | $166.66M | |
$13,919,584 | 9 | -30.43% | $134.57M | |
$5,524,590 | 7 | 7.40% | $136.02M | |
$299,343 | 6 | -44.75% | $170.11M | |
$13,001,183 | 5 | 58.75% | $156.22M | |
$193,101 | 3 | -25.20% | $168.53M | |
$19,848 | 2 | -11.42% | $177.49M | |
$63,731 | 1 | -19.50% | $167.72M |
| Increased Positions | 36 | +28.57% | 9M | +17.64% |
| Decreased Positions | 54 | -42.86% | 21M | -40.35% |
| New Positions | 8 | New | 2M | New |
| Sold Out Positions | 21 | Sold Out | 17M | Sold Out |
| Total Postitions | 108 | -14.29% | 41M | -22.71% |
| Matrix Capital Management Company, Lp | $19,125.00 | 19.39% | 13.96M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $3,979.00 | 4.03% | 2.9M | +19,768 | +0.69% | 2025-09-30 |
| Acadian Asset Management Llc | $3,898.00 | 3.95% | 2.85M | +46,132 | +1.65% | 2025-09-30 |
| Renaissance Technologies Llc | $3,186.00 | 3.23% | 2.33M | +795,802 | +52.03% | 2025-09-30 |
| Citadel Advisors Llc | $2,846.00 | 2.89% | 2.08M | +2M | +349.3% | 2025-09-30 |
| Tang Capital Management Llc | $2,124.00 | 2.15% | 1.55M | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $2,122.00 | 2.15% | 1.55M | +835,466 | +117.12% | 2025-09-30 |
| Two Sigma Advisers, Lp | $2,002.00 | 2.03% | 1.46M | +185,286 | +14.52% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $1,930.00 | 1.96% | 1.41M | +211,179 | +17.63% | 2025-09-30 |
| Morgan Stanley | $1,929.00 | 1.96% | 1.41M | +310,178 | +28.26% | 2025-09-30 |